Zepbound vs Wegovy side effects: A detailed comparison
Zepbound and Wegovy cause similar side effects — nausea, vomiting, diarrhea, and constipation — but they're not identical. SURMOUNT-5 trial data show Zepbound users were less likely to stop treatment due to side effects. Here's what that means for you.
Key highlights
- Zepbound and Wegovy are two powerful FDA-approved weight loss medications. Zepbound (tirzepatide) is a dual agonist at GLP-1 and GIP receptors, while Wegovy is a GLP-1 receptor agonist.
- Both medications have similar common side effects such as nausea, vomiting, constipation, diarrhea, stomachache, and bloating. However, the severity may differ.
- SURMOUNT-5 clinical trial results show that Zepbound has higher efficacy for weight loss and a greater gastrointestinal tolerance. Discontinuation rates were lower in the Zepbound group than in Wegovy users.
- Wegovy is the leader in lowering the risk of cardiovascular diseases. The medication is FDA-approved for cardiovascular risk reduction in obese and overweight individuals with established cardiovascular disease. Zepbound has not been approved by the FDA for this indication yet.
- There is no real winner between Zepbound and Wegovy, as the severity and frequency of side effects depend on an individual's tolerance and comorbidities.
- Some patients experience better tolerance to gastrointestinal side effects with Wegovy and can't handle Zepbound, and vice versa.
You might have seen the amazing before-and-after photos of people on weight loss medications such as Wegovy and Zepbound, but you have likely scrolled past horror stories about ‘Ozempic face’ or non-stop vomiting.
Both Wegovy and Zepbound have become increasingly popular for weight management, but their potential side effects may deter many people from starting treatment. While both drugs are highly effective for weight loss, they affect the body differently.
Some patients experience more side effects with Wegovy and find Zepbound more tolerable, and vice versa. The good news is that these side effects are manageable with lifestyle changes and dietary modifications. Your healthcare provider may make necessary dose adjustments to reduce the severity of these side effects.
This practical guide explains all the potential rare and common side effects, and will help you understand what you’re actually signing up for. It will compare Zepbound (tirzepatide) and Wegovy (semaglutide) side effects head-to-head so you can have an informed conversation with your doctor and know what to expect, the latest head-to-head clinical data (SURMOUNT-5), and help you decide which medication is right for your body.
Zepbound vs. Wegovy: Common side effects
Both Wegovy and Zepbound are incretin-based weight loss medications. Wegovy acts as a selective agonist at GLP-1 receptors only, while Zepbound is a dual agonist at GLP-1 and GIP receptors. Its dual action makes it more effective for weight management compared to Wegovy.
Wegovy is approved by the U.S. Food and Drug Administration (FDA) for:
- Reducing the risk of major adverse cardiovascular (CV) events such as cardiovascular death, non-fatal heart attack (myocardial infarction), or stroke in adults with existing cardiovascular disease and either obesity or overweight
- Managing excess weight in obese (body mass index 30 or more) and overweight (BMI 27 or more) patients with at least one weight-related condition
- Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults.
Zepbound is FDA-approved for reducing excess body weight and maintaining weight loss in adults with obesity or overweight with at least one weight-related comorbid condition (such as heart disease, high cholesterol levels, high blood pressure or hypertension, and dyslipidemia) and treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
STEP and SURMOUNT clinical trials assessed the safety and efficacy of Wegovy and Zepbound, respectively. These studies show that both medications have gastrointestinal side effects. The severity of these side effects is dose-dependent. The following are the most common side effects of these medications:
Nausea
Nausea is very common with Wegovy. It typically occurs when you start the medication or escalate the dosage. In STEP trials, 44% of Wegovy users experienced nausea, and 24.8% users had vomiting.
In SURMOUNT-1 clinical trials, the incidence of nausea was 24.6%, 33.3%, and 31% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively. Approximately 8.3%, 10.7%, and 12.2% of users experienced vomiting with these doses. These findings suggest that nausea and vomiting are common with both medications. The intensity of these side effects might be higher initially. You may feel less severe side effects as soon as your body starts to adapt. Think of nausea as a signal that the drug is working, but also a signal that you need to change how you eat.
Diarrhea
Diarrhea typically occurs when you eat something too fatty or greasy. Persistent diarrhea can lead to dehydration if not managed.
In STEP trials, the incidence of diarrhea was 31.5% in Wegovy users. In contrast, 18.7%, 21.2%, and 23% of Zepbound users experienced diarrhea with 5 mg, 10 mg, and 15 mg of Zepbound in the SURMOUNT-1 trial.
Constipation
Constipation is a common side effect of weight-loss medications that occurs due to slowed digestion. Patients may swing from diarrhea to constipation while taking these medications.
In the same trials, 23.4% of Wegovy users had constipation, while 11.7% of Zepbound users experienced constipation.
Headaches
Approximately 15.2% of Wegovy users reported headaches. There was a higher prevalence of headache in Wegovy users compared to Zepbound users.
Fatigue
Many users report feeling tired, especially in the first 24-48 hours after the shot and during the early treatment phase. Fatigue may occur, possibly due to a reduced-calorie diet rather than the medications. Ensure you are taking a nutrient-rich diet to prevent nutritional deficiencies that may cause fatigue.
Injection site reactions
Injection site reactions are more common with Zepbound (8.6%) than with Wegovy (5%). The symptoms of injection site reaction include rash, redness, itching, or pain at the injection spot (stomach, thigh, arm), formation of lumps, and infections.
Change the site of weekly injection, use the correct injection technique, and clean the area with alcohol or spirit swab to reduce the risk of these side effects. Wegovy pills are an alternative to injections for individuals who have a fear of needles.
| Adverse event | Wegovy® 2.4 mg (%) | Zepbound® 15 mg (%) |
|---|---|---|
| Nausea | 44% | 28% |
| Diarrhea | 30% | 23% |
| Vomiting | 24% | 13% |
| Constipation | 24% | 11% |
| Abdominal Pain | 20% | 10% |
| Dyspepsia | 9% | 10% |
| Fatigue | 11% | 7% |
| Dizziness | 8% | 4% |
| Abdominal Distension | 7% | 4% |
| Eructation (Belching) | 7% | 5% |
| Flatulence | 6% | 4% |
| Gastroesophageal Reflux Disease (GERD) | 5% | 5% |
| Hair Loss | 3% | 5% |
Lesser-known side effects
Gastrointestinal side effects are common with Zepbound and Wegovy, but you may experience a number of lesser-known side effects. These effects are typically secondary to rapid weight loss and metabolic changes instead of direct side effects of the medications.
“Ozempic Face” vs. skin laxity
The term “Ozempic face” has gained popularity on social media platforms and in clinical aesthetics. It is not medical terminology. Ozempic face refers to facial changes due to rapid weight loss, which include skin sagging, wrinkling, sunken cheeks, and an aged-looking face.
This phenomenon does not occur directly due to Wegovy or Zepbound. These medications promote fat loss in the body. Rapid loss of subcutaneous fat increases the visibility of nasolabial folds, marionette lines, and orbital hollowing. These changes result in a more aged or gaunt appearance, particularly in older individuals and patients with lower baseline skin elasticity.
Additionally, you may also experience skin loosening around the abdomen, thighs, and arms, and reduced skin recoil. These changes also occur due to rapid weight loss. You can follow these tips to prevent Ozempic face and skin laxity:
- Lose your body weight slowly and gradually. Aim for losing 1-2 lbs per week. Slow weight reduction may reduce the severity of these side effects.
- Add protein-rich foods to your meals to preserve muscle mass.
- You can also try resistance training to improve your body composition.
- Drink plenty of water throughout the day to keep your skin hydrated and youthful.
If you notice symptoms of Ozempic breasts or Ozempic face, you can consult a dermatologist or plastic surgeon to discuss your concerns.
Hair loss (telogen effluvium)
You may experience hair loss after using Wegovy or Zepbound. Telogen effluvium is excessive shedding of hair due to physical or mental stress, metabolic changes, and hormonal issues.
When your body experiences any kind of stress, a larger proportion of follicles prematurely enter the telogen phase (resting or shedding phase). Symptoms of telogen effluvium include diffuse hair loss when brushing or washing hair, hair thinning, and slow hair growth.
Hair loss with Wegovy or Zepbound occurs due to physiologic stressors such as rapid weight loss, caloric restriction, and metabolic shifts. Nutritional deficiencies can also cause hair loss. Here are a few tips to prevent telogen effluvium:
- Take a high-protein and nutrient-rich healthy diet daily.
- Get your serum iron, zinc, and vitamin levels checked to ensure you do not have any nutritional deficiencies.
- Avoid aggressive calorie deficits that trigger telogen effluvium.
- Consult a dermatologist if you experience excessive hair loss.
Heart rate changes
Both Wegovy (semaglutide) and Zepbound (tirzepatide) can cause a measurable increase in resting heart rate.
- In clinical trials, semaglutide 2.4 mg (Wegovy) increased mean heart rate by 1.2 beats per minute after 68 weeks.
- In the SURMOUNT-1 trial, tirzepatide increased pulse rate from baseline by 0.6, 2.3, and 2.6 beats per minute with 5-, 10-, and 15 mg doses, respectively, compared with 0.1 beats/minute in the placebo group.
Currently, there is no strong evidence that one drug consistently raises heart rate more than the other one. The exact mechanism of increased heart rate is still unknown, but it is hypothesized that increased sympathetic activity, the impact of GLP-1 receptor on the heart and autonomic nervous system, and changes in metabolism and body weight may increase heart rate.
Although this small increase in heart rate is not clinically significant, you must be cautious if you have pre-existing heart rhythm disorders (arrhythmias), advanced cardiovascular disease, or you already have a high resting heart rate.
Semaglutide (Wegovy) is FDA-approved for cardiovascular risk reduction. The medication has been tested in clinical trials for its safety. You do not need to worry about a mild increase in heart rate with Wegovy. Tirzepatide is still being studied for long-term cardiovascular outcomes, but has shown promising early data.
When taking Wegovy or Zepbound, watch for the following warning signs:
- Persistent resting heart rate significantly above baseline
- Palpitations
- Irregular heartbeat
- Dizziness
- Lightheadedness
- Shortness of breath
If any of these occur, consult your doctor immediately for medical advice.
Sulfur burps and heartburn
These side effects occur due to delayed digestion and slow gastric emptying, which cause prolonged food retention in the stomach and fermentation of gastric contents. Fermentation produces gases such as Hydrogen sulfide that cause “sulfur burps” or rotten egg odor.
Similarly, delayed stomach emptying increases gastric pressure and the acid reflux into the esophagus, which can cause gastroesophageal reflux disease (GERD). It can cause a burning sensation in the chest, an acid taste in the mouth, and regurgitation, especially after meals.
These side effects are common with both Wegovy and Zepbound. You can prevent them by following these measures:
- Eat Smaller but more frequent meals. Avoid heavy, high-fat, and greasy meals.
- Limit sulfur-rich foods such as eggs and certain cruciferous vegetables.
- Do not consume sugary drinks, fast food, fried meals, and carbonated beverages.
- Avoid lying down immediately after eating.
- Do not lie down immediately after meals. Go for a 10-15 minute digestive walk immediately after meals.
- Eat slowly to reduce air swallowing and chew your food properly.
If you have persistent gastric acid reflux, consult your doctor. They may recommend proton pump inhibitors (PPIs) or H2 blockers to manage these symptoms.
Muscle mass (sarcopenia)
Sarcopenia or lean muscle mass loss is one of the biggest emerging concerns with GLP-1 weight-loss drugs in 2026. Rapid weight loss from these medications can affect both fat and muscle mass, which may increase long-term risks such as weakness and metabolic slowdown. Weight-loss therapies (including GLP-1 drugs like Wegovy) are associated with some degree of lean mass loss alongside fat loss. This can contribute to “sarcopenic obesity,” in which body weight improves but muscle quality declines.
However, Zepbound has a dual mechanism (GIP and GLP-1) and may yield different results. Studies show greater fat mass reduction (75% of weight loss) than lean mass loss (25% of weight loss), which suggests a more favorable fat-to-muscle ratio. These studies also indicate that Zepbound preserves muscle quality and reduces fat infiltration in muscle tissue, rather than causing purely harmful muscle loss.
Wegovy pill vs. injection side effects
Both the oral (pill) and injectable Wegovy contain semaglutide, so they share the same gastrointestinal side effects, such as nausea, vomiting, diarrhea, and abdominal discomfort.
However, high-dose oral Wegovy may cause more stomach irritation, especially when you start the treatment. Wegovy pills require higher doses due to lower absorption, which increases the risk of gastrointestinal side effects.
Clinical studies and reviews report a slightly higher incidence of gastrointestinal adverse events with oral semaglutide. These include initial dyspepsia, nausea, and stomach upset, especially during dose escalation. In comparison, Wegovy injections offer steadier absorption and better GI tolerability.
Why do these drugs cause side effects?
Wegovy has semaglutide as an active ingredient. The medication mimics a naturally occurring GLP-1 hormone. The glucagon-like peptide-1 hormone regulates satiety. Wegovy has 94% structural similarity to this hormone. The medication binds GLP-1 receptors, mimics its action, sends satiety signals to the brain, and delays digestion by slowing gastric emptying.
Zepbound is a brand-name medication containing the active ingredient tirzepatide, which is a “twincretin,” or “dual agonist”. The medication mimics the action of GLP-1 and GIP hormones (glucose-dependent insulinotropic polypeptide) and occupies GLP-1 and GIP receptors. The addition of GIP may enhance fat breakdown and potentially alter the side effect profile. Dual agonism slows digestion, suppresses appetite, and promotes weight loss.
Both medications slow the rate at which food moves from your stomach into your intestine. That is why most side effects occur in the gastrointestinal tract. These include nausea, vomiting, bloating, stomach ache, abdominal discomfort, constipation, and diarrhea.
Semaglutide acts on GLP-1 receptors only, while Zepbound targets two receptors simultaneously. You might wonder whether targeting two receptors doubles the risk of side effects or whether both medications have the same side effect profile. Research studies suggest the opposite for some users. Zepbound may have fewer side effects.
Rare and serious risks
Wegovy and Zepbound have some rare but serious risks. If you experience any warning signs of these conditions, consult your doctor immediately.
Boxed warning: Thyroid C-Cell Tumors
The FDA has issued a boxed warning for Wegovy (semaglutide) and Zepbound (tirzepatide) about the risk of thyroid C-cell tumors and MEN 2 syndrome. Although no human studies have shown increased risk of these cancers, rodent studies show that they can increase the risk of thyroid C-cell tumors, particularly medullary C-cell tumors.
If you have a personal or family history of thyroid cancer or MEN2 (Multiple Endocrine Neoplasia syndrome type 2), these medications are not suitable for you.
Pancreatitis (inflammation of the pancreas)
Both medications can cause acute pancreatitis (inflammation of the pancreas), which can be serious and may require immediate medical attention.
Symptoms of acute pancreatitis are severe, sharp, and persistent upper abdominal pain that may radiate to the back, nausea, vomiting, and fever.
If you have these symptoms, stop taking the medication and seek urgent medical care right away.
Gallbladder issues (gallstones and gallbladder inflammation)
Both medications can also cause acute gallbladder problems such as gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). These problems typically occur due to rapid weight loss instead of the medication itself.
Warning signs of gallbladder issues may include:
- Pain in the upper right abdomen
- Fever
- Nausea
- Vomiting
- Jaundice (yellowing of the skin or eyes)
- Pain that worsens after eating fatty meals
Severe stomach problems (gastroparesis – “stomach paralysis”)
This is one of the most discussed concerns with GLP-1-based weight-loss drugs. These medications work by slowing gastric emptying to reduce appetite and improve fullness. In rare cases, they can cause paralysis of stomach muscles, which is known as gastroparesis. If you have persistent nausea, vomiting, a feeling of fullness, bloating, abdominal distension, and stomach pain that persists, these symptoms might be due to gastroparesis.
Consult your doctor for a detailed evaluation. The current data does not conclusively show one drug is worse than the other, but it is a risk factor for both.
Kidney health
Both Wegovy and Zepbound can cause acute kidney injury if you have severe dehydration from severe nausea, vomiting, or diarrhea. These medications do not directly affect kidney function. The warning signs of acute kidney injury (AKI) are low urine output, dizziness, extreme thirst, symptoms of severe dehydration, and weakness. If you experience these symptoms, stop taking these weight loss medications and visit your doctor immediately.
Additionally, drink enough fluids throughout the day to stay hydrated, especially during dose escalation or when you have severe gastrointestinal-related side effects. Your doctor may also monitor kidney function if you are at higher risk.
Mental health
Both Wegovy and Zepbound labels include depression and suicidal thoughts as rare and serious side effects of these medications. However, in January 2026, the FDA requested the removal of that warning from GLP-1 weight-management drug labels, including Wegovy and Zepbound. This decision was based on a review of clinical trials and post-marketing data, where the totality of evidence did not support a causal link between these medications and increased risk of suicidal ideation.
If you experience major mood changes, depression, self-harm thoughts, or unusual behavioral changes, consult your healthcare provider to seek medical advice.
Other rare but serious side effects include hypersensitivity or allergic reaction, hypoglycemia (low blood sugar levels), and increased risk of aspiration in anesthesia and sedation. Tell your doctor if you are using Wegovy or Zepbound before any procedure requiring sedation.
Head-to-head trial: SURMOUNT-5 results
The SURMOUT-5 clinical trial published in the New England Journal of Medicine directly compared semaglutide (Wegovy) and tirzepatide (Zepbound) in adults with overweight or obesity without type 2 diabetes over a period of 72 weeks. The primary outcome was the change in body weight.
Tirzepatide resulted in a greater reduction in body weight compared with semaglutide. Patients receiving tirzepatide achieved an average weight loss of approximately 20.2% of body weight, whereas those receiving semaglutide lost about 13.7% of their body weight. This indicates that tirzepatide led to roughly 6–7 percentage points more weight loss and was approximately 47% more effective than semaglutide.
In addition, a higher proportion of patients treated with tirzepatide achieved clinically significant weight loss thresholds, such as reductions of 10%, 15%, and 20% or more, compared with those treated with semaglutide.
Both medications had similar safety profiles. Gastrointestinal side effects, including nausea, vomiting, and diarrhea, were the most commonly reported adverse events in both groups. However, treatment discontinuation due to adverse events occurred in approximately 6.1% of patients in the tirzepatide (Zepbound) group and 8.0% in the semaglutide (Wegovy) group, indicating slightly lower discontinuation with tirzepatide. These results show that Zepbound is superior to Wegovy for promoting weight loss.
Zepbound vs. Wegovy: Which has worse side effects?
As mentioned in the SURMOUNT-5 clinical trial results, the discontinuation rate is lower with Zepbound compared to Wegovy users. Many patients report feeling “less sick” on Zepbound due to its dual mechanism, possibly because GIP modulation helps offset some of the GLP-1 harshness. Additionally, long-term side effects of Zepbound are still being studied. In comparison, Wegovy has a longer track record, so we know more about its long-term effects.
There is no clear ‘winner’ between Zepbound and Wegovy. The severity of side effects varies among individuals, depending on their body’s tolerance. Some people tolerate Wegovy better but can not handle Zepbound, and vice versa.
Managing side effects: How to survive the first few months
Side effects with Wegovy and Zepbound are usually transient (peak within 12-24 hours of dose administration) and subside over time. You might feel them at the beginning of the treatment or after dose escalation. Additionally, these side effects are dose-dependent but manageable. The following strategies may help improve tolerability, adherence, and long-term outcomes.
1. Take small, frequent meals
Both Wegovy and Zepbound delay gastric emptying. Large meals can worsen gastrointestinal side effects such as bloating, nausea, vomiting, and abdominal discomfort. Eat 4–6 small meals per day instead of taking large 2-3 meals. Stop eating at the first sign of fullness to prevent overeating, which triggers nausea.
Do not keep your stomach empty, as an empty stomach can also worsen nausea. Take smaller but more frequent meals to keep your blood sugar levels steady.
2. The protein rule (70–100 g/day)
Protein intake is essential to preserve lean muscle mass during rapid weight loss. Aim for 70-100 grams of protein per day to reduce the risks of fatigue, weakness, telogen effluvium (rapid hair loss), and blood sugar spikes.
Add high-protein foods such as eggs, Greek yogurt, white chicken or poultry, fish, and protein shakes to your diet to prevent lean muscle loss and stabilize blood sugar levels.
3. The “bland diet” protocol (early phase)
Follow a bland diet during the early phase of treatment to avoid irritating your stomach lining. You can add crackers, rice, bananas, toast, and clear broth to your diet.
Avoid fried foods, high-fat meals, heavy cream-based sauces, and sodas that delay your stomach emptying and worsen gastrointestinal side effects such as nausea, abdominal discomfort, stomach ache, and burping.
4. Hydration and electrolytes
Drink plenty of water throughout the day to stay adequately hydrated. Drink at least one litre of water per day. Persistent vomiting or diarrhea can cause dehydration and electrolyte imbalances. Symptoms of dehydration are headache, rapid heartbeat, fatigue, dizziness, hypotension, sunken eyes, dry mouth, and confusion.
If you have mild to moderate dehydration, consume oral rehydration solution (ORS). In case of severe dehydration, immediately visit your doctor as it can cause acute kidney injury.
If you are in a hot or dehydrating environment, increase your water intake to prevent these side effects.
5. OTC medications (when appropriate)
You can use over-the-counter medications such as Pepto-Bismol (bismuth subsalicylate) to relieve gastrointestinal side effects. The medication coats the inner lining of the stomach and provides a soothing or calming effect. It is used for upset stomach, diarrhea, indigestion, stomachache, and bloating.
Magnesium can also help relieve constipation. Magnesium citrate and magnesium hydroxide act as laxatives and soften stools. These are only used for short periods, as long-term use can be harmful.
You can also try over-the-counter home remedies, such as ginger tea or capsules, to help prevent nausea and vomiting. If you have severe or persistent vomiting, your doctor may prescribe antiemetics like Zofran (ondansetron) to reduce the severity of these side effects.
6. Inject at night
The timing of Wegovy and Zepbound injections also influences the severity of side effects. Typically, side effects peak within a few hours of administering the injection. You can inject these medications at night before bedtime to sleep through early symptoms. Additionally, avoid large meals before injection to reduce the severity of GI effects.
7. Thigh vs. abdomen injection site
The choice of injection site may also influence the severity of side effects. Some patients report fewer side effects with thigh injections and more severe gastrointestinal symptoms with abdominal injections. It is hypothesized that these differences might be due to differences in absorption rate and bioavailability of the medication at different sites. However, no clinical studies compare the severity of side effects of thigh and abdominal injections.
Rotate injection sites every week to prevent injection-site reactions, which include skin infections, redness, pain, swelling, and lumps.
8. Don’t rush the dose escalation
Most side effects occur when you increase the dose of GLP-1 medication. Gradually increase your dosage as prescribed by your healthcare provider to give your body enough time to adapt to physiological changes. Rapid escalation may intensify side effects.
If you experience severe side effects after dose escalation, consult your healthcare provider. They may lower the dose, delay escalation, or keep you on the previous dose for the next few weeks.
9. Electrolytes (especially for fatigue & headaches)
You are more prone to developing an electrolyte imbalance on Wegovy and Zepbound for several possible reasons. These may include reduced calorie intake, which lowers electrolyte intake, fluid shifts from weight loss, and electrolyte loss from diarrhea and vomiting. Symptoms of electrolyte imbalance are fatigue, headaches, brain fog, confusion, and muscle weakness.
Use sugar-free electrolyte powders or solutions to restore electrolytes in your body. Additionally, take a nutrient-rich diet to prevent electrolyte imbalance.
Cost and insurance coverage
The list price of semaglutide is higher than that of tirzepatide. The list price for Wegovy is around $1,349 per month, as compared to $1,086 per month for Zepbound.
Wegovy Savings Program
Novo Nordisk, the manufacturer of Wegovy, offers a Wegovy savings offer. If your insurance plan covers Wegovy, the savings offer can reduce the out-of-pocket cost to as low as $25.
To be eligible for the Wegovy savings card, you must have commercial insurance that covers Wegovy and a valid Wegovy prescription, be at least 18 years old, and be a legal resident of the United States. Additionally, you should not be enrolled in any government-funded healthcare program, including Medicare, Medicaid, TRICARE, VA, or similar programs.
Here are Wegovy prices through NovoCare Pharmacy for self-pay patients:
- Wegovy Pills 1.5 mg – $149/month
- Wegovy Pills 4 mg – $199/month
- Wegovy Pills 19 mg – $299/month
- Wegovy Pills 25 mg – $299/month
- Wegovy Pen 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg – $349/month
- Wegovy Pen 7.2 mg – $399/month
Zepbound Savings Program
Eli Lilly offers a Zepbound Savings Card for patients who have commercial or private insurance. If your insurance plan covers Zepbound, you may pay as little as $25 for your prescription.
To be eligible for the savings card, you must have commercial insurance that covers Zepbound and a valid prescription for Zepbound. You must also be a resident of the United States and at least 18 years old. If you are enrolled in government-funded healthcare programs such as Medicare, Medicaid, TRICARE, VA, or DoD, you are not eligible for this savings card.
Here are Zepbound Single-Dose Vial and Zepbound KwikPen prices for self-pay patients through LillyDirect:
- Zepbound 2.5 mg – $299/month
- Zepbound 5 mg – $399/month
- Zepbound 7.5 mg, 10 mg, 12.5 mg, 15 mg – $449/month
FAQs
Can I switch from Wegovy to Zepbound to avoid side effects?
Yes, you may switch from Wegovy to Zepbound if you experience severe side effects with Wegovy. However, always consult with your doctor first before switching medications. They may adjust the Wegovy dose and recommend lifestyle modifications and over-the-counter medications. If your symptoms do not improve, they may switch to Zepbound after a washout period (approximately 7 days).
Do the side effects ever go away completely?
For most patients, acute side effects such as nausea, bloating, abdominal discomfort, and burping typically fade within the first 4-8 weeks as the body adjusts to the physiological changes. However, chronic constipation or heartburn may persist longer. You will need to change your dietary habits to completely resolve these side effects.
How long do the side effects last?
The common side effects of Wegovy and Zepbound are transient. They typically appear when you start the medication or increase the dose, and subside within the first 4-8 weeks as your body adapts. However, some side effects, such as constipation and heartburn, may persist.
Does insurance cover one or the other based on side effects?
No, insurance does not cover these medications based on side effects. Insurance companies require valid prescriptions from authorized healthcare providers for FDA-approved indications to cover weight loss medications.
Which is better for heart health?
Wegovy is FDA-approved for reducing cardiovascular risk in high-risk patients. A 2023 SELECT trial published in the New England Journal of Medicine (NEJM) enrolled 17,604 patients with overweight or obesity and established cardiovascular disease who used semaglutide (2.4 mg) or placebo. After 39.8 weeks, major adverse cardiovascular events (MACE) occurred in 6.5% of patients compared to 8% in the placebo group.
Additionally, patients on semaglutide also lost 15% of their body weight and showed a decrease in blood pressure. Tirzepatide (Zepbound and Mounjaro) has not yet demonstrated clinical efficacy for heart health, so Wegovy currently holds the edge in this specific category.
What if I vomit after taking my dose?
If you vomit shortly after taking the pill (if you switch to the oral version) or the injection, do not take the medication again. Wait for your next scheduled dose.
Is the Wegovy pill easier on the stomach than the injection?
No, the Wegovy pill is not necessarily easier on the stomach than the injection.
According to the FDA label, semaglutide tablets can cause severe gastrointestinal adverse reactions and require careful monitoring.
Both tablet and injection forms share similar GI side effects like nausea and vomiting, as both belong to the same class of medications. Additionally, oral Wegovy also delays gastric emptying, which can worsen GI symptoms and affect how other medications are absorbed.
Does Wegovy or Zepbound interfere with birth control?
Yes, Wegovy and Zepbound can interfere with birth control pills. Healthcare providers recommend switching to a non-oral contraceptive method (Intrauterine device, contraceptive implant, injection such as Depo-Provera, or vaginal ring or transdermal patch) or add a barrier method of contraception (such as condoms) for 4 weeks after starting the treatment and for 4 weeks after each dose escalation.
Zepbound delays gastric emptying and may affect the absorption of oral birth control pills. Wegovy (semaglutide) does not significantly reduce absorption directly, but it commonly causes gastrointestinal side effects such as nausea and vomiting. If you experience vomiting shortly after taking an oral contraceptive, the pill may not be fully absorbed, which reduces the efficacy of contraceptives. This is considered a mechanical risk, not a pharmacokinetic interaction.
Conclusion: Understanding the side effects of Zepbound vs. Wegovy
Both Wegovy and Zepbound are powerful medications for weight loss with similar side effect profiles, but they are not identical. Common side effects of these medications are nausea, vomiting, diarrhea, bloating, abdominal discomfort, stomachaches, and constipation. These side effects are typically short-term and fade over time as your body adapts to physiological changes.
Although both are transformative, Zepbound currently holds the edge in promoting greater weight loss and better GI tolerability (for many). However, the severity or intensity of side effects may vary among individuals depending on their body’s tolerance and health conditions. Some patients may tolerate Zepbound better but can’t handle Wegovy, and vice versa.
